Anti-markup provisions delayed one year; 2 exceptions

Why This Topic Matters

The article helps readers understand which parts of the Medicare anti-markup policy were postponed, which parts remained in effect, and why the rule could affect reimbursement for diagnostic services performed outside the billing physician’s office. It is important for practices that bill for purchased diagnostic components or pathology-related services and need to track CMS timing and clarification efforts.

Article Sections

1. Delay of the anti-markup rule

   Summarizes the CMS delay, the revised effective timing, and the scope of the postponement. It also notes the service categories that were treated differently.

2. Office definition and CMS clarification plans

   Discusses concerns about how CMS defined the billing physician’s office and the agency’s stated plan to provide clarification or further rulemaking. The section focuses on the policy uncertainty that prompted industry concern.

3. Technical component

   Covers the portion of the policy that continued to apply to diagnostic testing components during the earlier timeframe. It explains the article’s focus on how this affected purchased or offsite testing arrangements.

4. Pathology

   Reviews the article’s discussion of pathology-related services, the building-related distinctions mentioned by CMS, and the specialties most likely to notice the impact. The section also addresses the article’s discussion of practice structure and service location.

5. Professional fees

   Addresses the postponed portion of the policy tied to professional service billing and the circumstances described by the article as potentially affected later. It also notes the article’s broader reimbursement context.

6. Additional considerations

   Summarizes the article’s broader reimbursement and compliance observations, including how the policy was described relative to other federal fraud and abuse rules. It also mentions the article’s discussion of the rulemaking process.